Filing Details

Accession Number:
0001209191-18-034209
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-30 17:32:31
Reporting Period:
2018-05-30
Accepted Time:
2018-05-30 17:32:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1659323 Iterum Therapeutics Plc ITRM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1245624 James Healy C/o Iterum Therapeutics Limited, Blk 2
Fl. 3, Harcourt Centre, Harcourt St.
Dublin L2 2
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2018-05-30 721,408 $0.00 721,408 No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
Ordinary Shares Acquisiton 2018-05-30 275,446 $0.00 996,854 No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
Ordinary Shares Acquisiton 2018-05-30 229,660 $0.00 1,226,514 No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
Ordinary Shares Acquisiton 2018-05-30 500,000 $13.00 1,726,514 No 4 P Indirect By Sofinnova Venture Partners IX, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
No 4 C Indirect By Sofinnova Venture Partners IX, L.P.
No 4 P Indirect By Sofinnova Venture Partners IX, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Preferred Shares Disposition 2018-05-30 721,408 $0.00 721,408 $0.00
Ordinary Shares Series B-1 Preferred Shares Disposition 2018-05-30 275,446 $0.00 275,446 $0.00
Ordinary Shares Series B-2 Preferred Shares Disposition 2018-05-30 229,660 $0.00 229,660 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  2. These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.
  3. The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  4. The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  5. Not applicable.